7 May 2018 - - Berkeley, California-based genome editing company Caribou Biosciences, Inc. has appointed Timothy F. Herpin, Ph.D. as its first chief business officer, the company said.
In this role, Herpin will lead the company's efforts in the areas of strategic partnerships, licensing agreements, and other value creation opportunities.
Herpin joins Caribou from AstraZeneca where he served as vice president and head of transactions.. Prior to that, he served as vice president of strategic partnering and business development for oncology.
Before AstraZeneca, Herpin spent eight years in the business development organization at Bristol-Myers Squibb covering both search and evaluation, as well as transactions in multiple disease areas.
Herpin received his undergraduate degree in Chemistry from the École Polytechnique in France, his Ph.D. in Chemistry from the University College London, UK, and an M.B.A. from the NYU Stern School of Business.
Caribou's tools and technologies provide transformative capabilities to therapeutic development, agricultural biotechnology, industrial biotechnology, and basic and applied biological research.
The company offers licenses to its CRISPR-Cas9 foundational IP in multiple fields including research tools, internal research use, diagnostics, and industrial biotechnology.